Market Place
Sourcing Support
Aura Biosciences Joins 8th Evercore Healthcare Conference
24 Nov 2025 //
GLOBENEWSWIRE
Bel-sar Phase 1 Trial Data in NMIBC Presented at EAU Congress
24 Mar 2025 //
GLOBENEWSWIRE
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
26 Feb 2024 //
BUSINESSWIRE
Aura Announces First Patient Dosed in Phase 3 Trial Evaluating Bel-sar
07 Dec 2023 //
BUSINESSWIRE
Aura Biosciences Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
08 Nov 2023 //
BUSINESSWIRE
Aura Biosciences Receives FDA Agreement SPA for CoMpass Phase 3 Trial of Bel-sar
06 Nov 2023 //
BUSINESSWIRE
Aura Biosciences Announces Pricing of Public Offering of Common Stock
06 Nov 2023 //
BUSINESSWIRE
Aura to Present Phase 2 Data Evaluating Suprachoroidal Administration of Bel-sar
31 Oct 2023 //
BUSINESSWIRE
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
02 Oct 2023 //
BUSINESSWIRE
Aura Biosciences Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
24 May 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
12 May 2023 //
BUSINESSWIRE
Aura Biosciences Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
09 Feb 2023 //
BUSINESSWIRE
Aura Biosciences Announces Proposed Public Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Announces Pricing of Public Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Reports 3Q 2022 Financial Results & Provides Clinical Develop
10 Nov 2022 //
BUSINESSWIRE
Aura Announces Global Pha3 Trial Designwith Suprachoroidal Route Administration
10 Nov 2022 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
03 Nov 2022 //
BUSINESSWIRE
Aura Biosciences Announces Interim Phase 2 Data Evaluating AU-011
03 Oct 2022 //
BUSINESSWIRE
Aura details second administration route of its ocular oncology drug from PIII
03 Oct 2022 //
ENDPTS
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in Japan
27 Sep 2022 //
KOREABIOMED
Aura to Present Phase 2 Data Evaluating Suprachoroidal Administration of AU-011
27 Sep 2022 //
BUSINESSWIRE
Aura Bio to Present PII Safety Data Evaluating Suprachoroidal
07 Sep 2022 //
BUSINESSWIRE
Aura to Present Belzupacap Sarotalocan Data from Studies at EURETINA Congress
01 Sep 2022 //
BUSINESSWIRE
Aura Biosciences Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
02 Aug 2022 //
BUSINESSWIRE
Aura Biosciences Receives FDA FTD for Belzupacap Sarotalocan (AU-011)
30 Jun 2022 //
BUSINESSWIRE
Aura Bio Reports Topline Data from Retrospective Study of Belzupacap Sarotalocan
22 Jun 2022 //
BUSINESSWIRE
Aura Bio to Present Updated Belzupacap Sarotalocan Data on Multiple Studies
17 Jun 2022 //
BUSINESSWIRE
Aura Bio Publishes Preclinical Data of VDCs with Immune Checkpoint Inhibitors
26 May 2022 //
BUSINESSWIRE
Aura Biosciences to Participate in Upcoming Investor Conferences
25 May 2022 //
BUSINESSWIRE
Aura Biosciences Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
03 May 2022 //
BUSINESSWIRE
Aura Bio Bags ODD for AU-011 by EC for the Treatment of Uveal Melanoma
21 Mar 2022 //
BUSINESSWIRE
Aura Bio to Present Preclinical Data of AU?011 onTumors at 2022 AACR
08 Mar 2022 //
BUSINESSWIRE
Aura Biosciences to Participate at 42nd Annual Cowen Conference
28 Feb 2022 //
BUSINESSWIRE
Aura Bio to Present Preclinical Data Demonstrating Applicability of AU-011
14 Feb 2022 //
BUSINESSWIRE
Aura Biosciences to Participate at the 11th Annual SVB Leerink Conference
09 Feb 2022 //
BUSINESSWIRE
Aura Biosciences Reports Q3 2021 Financial Results
24 Nov 2021 //
BUSINESSWIRE
Aura Presents Final Phase 1b/2 Data for its first Virus-Like Drug , AU-011
15 Nov 2021 //
BUSINESSWIRE
Aura Bio Presents Phase 1b/2 Data for AU-011 in Choroidal Melanoma at AAO 2021
15 Nov 2021 //
BUSINESSWIRE
Spooky SPAC season and a $180M Entrada onto Wall Street
30 Oct 2021 //
MARKETWATCH
Aura Biosciences Announces Pricing of IPO
28 Oct 2021 //
BUSINESSWIRE
Aura Biosciences Aims For $75 Million IPO
25 Oct 2021 //
SEEKINGALPHA
IPO floodgates open up after summer lull as five more biotechs file for Nasdaq
13 Oct 2021 //
ENDPTS
Aura Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal of AU-011
12 Oct 2021 //
PRESS RELEASE
Aura Presents Interim Phase 2 Safety Data of AU-011 in Choroidal Melanoma
11 Oct 2021 //
BUSINESSWIRE
Aura Biosciences files for $100M IPO
08 Oct 2021 //
SEEKINGALPHA
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
17 Jun 2021 //
BUSINESSWIRE
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
16 Jun 2021 //
BUSINESSWIRE
Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors
08 Jun 2021 //
BUSINESSWIRE
Aura Biosciences Presents New Preclinical AU-011 Data (ARVO) 2021
03 May 2021 //
BUSINESSWIRE
Aura Biosciences Announces Publication of Data in Cancer Immunology Research
14 Apr 2021 //
NEUROAMERICA
Aura Expands Executive Leadership Team with the Appointment of Mark De
24 Mar 2021 //
BUSINESSWIRE
